FindTrial
Sign In

A Preliminary Study on the Prediction of Outcomes of Patients with Castration-Resistant Prostate Cancer Treated by Abiraterone Using AR-FL and AR-V7 Transcript Levels in Peripheral Blood and Serum Levels of Neuroendocrine Tumor Markers

A Study on the Prediction of Outcomes of Patients with Castration-Resistant Prostate Cancer Treated by Abiraterone Using AR-FL and AR-V7 Transcript Levels in Peripheral Blood and Serum Levels of Neuroendocrine Tumor Markers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-POC-17011797
Enrollment
Unknown
Registered
2017-06-29
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-Resistant Prostate Cancer

Interventions

Two cohorts:None

Sponsors

The General Hospital of People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. pathological diagnosis of prostate cancer; 2. castration-level testosterone (<50 ng/dl or 1.73 nmol/l); 3. existence of PSA progression; 4. agree to receive Abiraterone treatment.

Exclusion criteria

Exclusion criteria: received other therapies during the Abiraterone treatment (castration therapy excluded)

Design outcomes

Primary

MeasureTime frame
Transcript levels of AR-FL and AR-V7;the level of neuron-specific enolase;the level of pro-gastrin-releasing peptide;—

Countries

China

Contacts

Public ContactJiangping Gao

The General Hospital of People's Liberation Army

jpgao@163.com+86 13911027586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026